NTRK1 and neoplasm: ,19 Notably, all previously reported cases involved minimal residual tumor volume at the time of TRK inhibitor initiation, whereas our patient received entrectinib in the context of a substantial 6 cm residual tumor, highlighting the potential of TRK inhibition even in cases with high tumor volume.